Oyster Point Pharma Inc Stock News

OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of 9.87% and 24.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) announced it is buying Oyster Point Pharma (OYST). This is why.

Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET

Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and Tear Film Cytokine Research Two Featured Presentations will Include a Post-Hoc Analysis

PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization o

Oyster Point Pharma, Inc. (NASDAQ:OYST ) Q2 2022 Results Conference Call August 11, 2022 4:30 PM ET Company Participants Arty Ahmed - Vice President, Investor Relations Dr. Jeffrey Nau - President and

OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -14.02% and 2.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Conference Call and Webcast Scheduled for August 11, 2022, 4:30 p.m. ET

The consensus price target hints at a 423.5% upside potential for OYSTER PT PHARM (OYST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings

OYST has an approved product that is highly competitive against a blockbuster drug. They seem to have executed commercialization pretty well, except in the bottom line.

Plan to Continue to Drive TYRVAYA® Launch with Approximately 150-200 Field-Based Sales Resources

Scientific Poster Examines Effects of Treatment in Broad Spectrum of Dry Eye Disease Patients Scientific Poster Examines Effects of Treatment in Broad Spectrum of Dry Eye Disease Patients

Oyster Point Pharma, Inc. (NASDAQ:OYST ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Arty Ahmed - Vice President, Investor Relations Dr. Jeffrey Nau - President and CE

OYST earnings call for the period ending March 31, 2022.

OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -2.86% and 31.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?